Insilico Medicine

Insilico Medicine is a clinical-stage AI-driven drug discovery company that has achieved a historic milestone: advancing the first drug both discovered and designed entirely by AI into Phase 2 clinical trials. Its Pharma.AI platform integrates three engines — PandaOmics for target discovery, Chemistry42 for molecular generation, and inClinico for clinical trial prediction. The lead compound rentosertib (INS018_055) showed positive Phase 2a results in idiopathic pulmonary fibrosis, with dose-dependent lung function improvement.

Pharma.AI integrates three complementary engines: PandaOmics (multi-omics target discovery), Chemistry42 (generative molecular design), and inClinico (clinical trial outcome prediction). This end-to-end platform identified a novel target (TNIK) and designed a clinical candidate in under 18 months.